Pharmacy

Your Article Summary

See Latest Articles

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott, 06/24/09

Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Hibiscus Sabdariffa L. Tea (Tisane) Lowers Blood Pressure in Prehypertensive and Mildly Hypertensive Adults
The Journal of Nutrition, 12/17/09

Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic
Hypertension Research, 12/17/09

Role of coenzyme Q10 in cardiac disease, hypertension and Meniere-like syndrome
Pharmacology & Therapeutics, 12/17/09

 See all of Cardiac/Hypertension

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09

Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug Approvals

Today in Drug/Product Alerts...keeping you current

Receive free subspecialty "5-minute updates" via email

Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09

 See all of Drug/Product Alerts